Modulation of the discriminative stimulus effects of triazolam across the menstrual cycle phase in healthy pre-menopausal women

Shanna Babalonis, Cleeve S. Emurian, Catherine A. Martin, Joshua A. Lile, Thomas H. Kelly

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Pre-clinical studies indicate that changes in progesterone levels across menstrual cycle phases modulate the behavioral effects of sedative drugs acting at GABAA receptor sites. In this study, seven healthy women learned to discriminate triazolam (0.25 mg/70 kg) from placebo. After acquiring the discrimination, a range of triazolam doses (0.00, 0.06, 0.12 and 0.25 mg/70 kg) was tested during the early follicular and mid-luteal menstrual cycle phases. During the mid-luteal phase, when progesterone levels were elevated, 0.12 mg/70 kg triazolam was identified as the active triazolam training dose (0.25 mg/70 kg), whereas 0.12 mg/70 kg triazolam was identified as placebo during the early follicular phase, when progesterone levels were low. Triazolam engendered prototypical sedative effects on subjective effect, performance and cardiovascular measures that were generally independent of cycle phase. These results suggest that the discriminative stimulus effects of the positive GABAA modulator, triazolam, are sensitive to menstrual cycle phase in healthy adult women.

Original languageEnglish
Pages (from-to)276-280
Number of pages5
JournalDrug and Alcohol Dependence
Volume94
Issue number1-3
DOIs
StatePublished - Apr 1 2008

Bibliographical note

Funding Information:
Funding : Funding for this study was provided by DA-09098 from the National Institute on Drug Abuse (NIDA, THK) and P20 RR 15592 from the National Center for Research Resources (NCRR, THK); Shanna Babalonis was supported by T32 DA-007304 (NIDA) during the preparation of this manuscript. NCRR and NIDA had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.

Keywords

  • Drug discrimination
  • Human
  • Menstrual cycle
  • Progesterone
  • Triazolam

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Modulation of the discriminative stimulus effects of triazolam across the menstrual cycle phase in healthy pre-menopausal women'. Together they form a unique fingerprint.

Cite this